Author: Thomas S.M. Burke J.F.
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.7, Iss.1, 1997-01, pp. : 9-15
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Genetics Institute, the US biotechnology company, was part of the first wave of biotechnology start-ups in the 1980s. Although it was a leading company in the development of important therapeutics such as tissue plasminogen activator (t-PA) and erythropoietin (EPO), the Company was unable to market these products in the US as a consequence of patent disputes with Amgen and Genentech. The Company now derives the majority of its income from sales of Factor VIII, EPO and t-PA in Europe and Japan. Its future lies in finding therapeutic applications for interleukins (ILs) and bone morphogenetic proteins (BMPs). A parallel strategy is in the licensing of its yeast secretion technology for the discovery of novel secreted proteins.
Related content
Secreted Proteins of the Oviduct
Cells Tissues Organs, Vol. 166, Iss. 2, 2008-07 ,pp. :
Genetics of Ribosome-Inactivating Proteins
Mini Reviews in Medicinal Chemistry, Vol. 4, Iss. 5, 2004-06 ,pp. :
Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 12, 2006-01 ,pp. :
Future prospects in respiratory syncytial virus genetics
By Kimman Tjeerd G Janssen Riny Hoebee Barbara
Future Virology, Vol. 1, Iss. 4, 2006-07 ,pp. :